Sl-EDGE: Network Slicing at the Edge

Network slicing of multi-access edge computing (MEC) resources is expected to be a pivotal technology to the success of 5G networks and beyond. The key challenge that sets MEC slicing apart from traditional resource allocation problems is that edge nodes depend on tightly-intertwined and strictly-constrained networking, computation and storage resources. Therefore, instantiating MEC slices without incurring in resource over-provisioning is hardly addressable with existing slicing algorithms. The main innovation of this paper is Sl-EDGE, a unified MEC slicing framework that allows network operators to instantiate heterogeneous slice services (e.g., video streaming, caching, 5G network access) on edge devices. We first describe the architecture and operations of Sl-EDGE, and then show that the problem of optimally instantiating joint network-MEC slices is NP-hard. Thus, we propose near-optimal algorithms that leverage key similarities among edge nodes and resource virtualization to instantiate heterogeneous slices 7.5x faster and within 0.25 of the optimum. We first assess the performance of our algorithms through extensive numerical analysis, and show that Sl-EDGE instantiates slices 6x more efficiently then state-of-the-art MEC slicing algorithms. Furthermore, experimental results on a 24-radio testbed with 9 smartphones demonstrate that Sl-EDGE provides at once highly-efficient slicing of joint LTE connectivity, video streaming over WiFi, and ffmpeg video transcoding

Protein kinase activity of phosphoinositide 3-kinase regulates cytokine-dependent cell survival

Extent: 14 p.The dual specificity protein/lipid kinase, phosphoinositide 3-kinase (PI3K), promotes growth factor-mediated cell survival and is frequently deregulated in cancer. However, in contrast to canonical lipid-kinase functions, the role of PI3K protein kinase activity in regulating cell survival is unknown. We have employed a novel approach to purify and pharmacologically profile protein kinases from primary human acute myeloid leukemia (AML) cells that phosphorylate serine residues in the cytoplasmic portion of cytokine receptors to promote hemopoietic cell survival. We have isolated a kinase activity that is able to directly phosphorylate Ser585 in the cytoplasmic domain of the interleukin 3 (IL-3) and granulocyte macrophage colony stimulating factor (GM-CSF) receptors and shown it to be PI3K. Physiological concentrations of cytokine in the picomolar range were sufficient for activating the protein kinase activity of PI3K leading to Ser585 phosphorylation and hemopoietic cell survival but did not activate PI3K lipid kinase signaling or promote proliferation. Blockade of PI3K lipid signaling by expression of the pleckstrin homology of Akt1 had no significant impact on the ability of picomolar concentrations of cytokine to promote hemopoietic cell survival. Furthermore, inducible expression of a mutant form of PI3K that is defective in lipid kinase activity but retains protein kinase activity was able to promote Ser585 phosphorylation and hemopoietic cell survival in the absence of cytokine. Blockade of p110α by RNA interference or multiple independent PI3K inhibitors not only blocked Ser585 phosphorylation in cytokine-dependent cells and primary human AML blasts, but also resulted in a block in survival signaling and cell death. Our findings demonstrate a new role for the protein kinase activity of PI3K in phosphorylating the cytoplasmic tail of the GM-CSF and IL-3 receptors to selectively regulate cell survival highlighting the importance of targeting such pathways in cancer.Daniel Thomas, Jason A. Powell, Benjamin D. Green, Emma F. Barry, Yuefang Ma, Joanna Woodcock, Stephen Fitter, Andrew C.W. Zannettino, Stuart M. Pitson, Timothy P. Hughes, Angel F. Lopez, Peter R. Shepherd, Andrew H. Wei, Paul G. Ekert and Mark A. Guthridg

Resource Queuing System with Preemptive Priority for Performance Analysis of 5G NR Systems

One of the ways to enable smooth coexistence of ultra reliable low latency communication (URRLC) and enhances mobile broadband (eMBB) services at the air interface of perspective 5G New Radio (NR) technology is to utilize preemptive priority service. In this paper, we provide approximate analysis of the queuing system with random resource requirements, two types of customers and preemptive priority service procedure. The distinctive feature of the systems – the random resource requirements – allows to capture the essentials of 5G NR radio interface but inherently increases the complexity of analysis. We present the main performance metrics of interest including session drop probability and system resource utilization as well as assess their accuracy by comparing with computer simulations. The developed model is not inherently limited to URLLC and eMBB coexistence and can be utilized in performance evaluation of 5G NR systems with priority-based service discipline at the air interface, e.g., in context of network slicing. Among other conclusions we explicitly show that both session drop and interruption probabilities of low priority traffic heavily depend not only on the intensity of high priority traffic but on stochastic characteristics of the resource request distribution.acceptedVersionPeer reviewe

Inhibition of PI3K Prevents the Proliferation and Differentiation of Human Lung Fibroblasts into Myofibroblasts: The Role of Class I P110 Isoforms

Idiopathic pulmonary fibrosis (IPF) is a progressive fibroproliferative disease characterized by an accumulation of fibroblasts and myofibroblasts in the alveolar wall. Even though the pathogenesis of this fatal disorder remains unclear, transforming growth factor-β (TGF-β)-induced differentiation and proliferation of myofibroblasts is recognized as a primary event. The molecular pathways involved in TGF-β signalling are generally Smad-dependent yet Smad-independent pathways, including phosphatidylinositol-3-kinase/protein kinase B (PI3K/Akt), have been recently proposed. In this research we established ex-vivo cultures of human lung fibroblasts and we investigated the role of the PI3K/Akt pathway in two critical stages of the fibrotic process induced by TGF-β: fibroblast proliferation and differentiation into myofibroblasts. Here we show that the pan-inhibitor of PI3Ks LY294002 is able to abrogate the TGF-β-induced increase in cell proliferation, in α- smooth muscle actin expression and in collagen production besides inhibiting Akt phosphorylation, thus demonstrating the centrality of the PI3K/Akt pathway in lung fibroblast proliferation and differentiation. Moreover, for the first time we show that PI3K p110δ and p110γ are functionally expressed in human lung fibroblasts, in addition to the ubiquitously expressed p110α and β. Finally, results obtained with both selective inhibitors and gene knocking-down experiments demonstrate a major role of p110γ and p110α in both TGF-β-induced fibroblast proliferation and differentiation. This finding suggests that specific PI3K isoforms can be pharmacological targets in IPF

Vps34 PI 3-kinase inactivation enhances insulin sensitivity through reprogramming of mitochondrial metabolism

Postdoctoral fellowships were from EU Marie Curie (PIEF-GA-2009–252916) and EMBO (ALTF 753–2010) for SA and EU Marie Curie (PIIF-GA-2009–252846) for C.C. J. M.H. was a recipient of a doctoral fellowship from Eisai UK Ltd. Work in our laboratories was supported as follows: BV: MRC [G0700755], BBSRC (BB/I007806/1 and BB/ M013278/1), CRUK (C23338/A15965), the Ludwig Institute for Cancer Research and the National Institute for Health Research (NIHR) UCL Hospitals Biomedical Research Centre; J.M.B.: NIH AG039632, GM112524. and the Albert Einstein Diabetes Research and Training Center Animal Physiology Core DK020541; E.G.: Barry Reed Cancer Research fund; G.S.: BBSRC (BB/L020874/1) and B.H.F.; S.S.: Anatomical Society of Great Britain (GT) and a Wellcome Trust Career Development Fellowship 074246/Z04/Z (S.S.); R.K.S.: Wellcome Trust (WT098498) and M.R.C. (MRC_MC_UU_12012/5); S.A. T. and L.C.: the Francis Crick Institute, which receives its core funding from CRUK (FC001187), MRC (FC001187), and the Wellcome Trust (FC001187); Y.-L.C.: the CRUK Cancer Imaging Centre in association with the MRC and DoH (England) grant C1060/ A10334, C1060/A16464, NHS funding to the NIHR BRC; B.P.: Inserm and the Fondation pour la recherche médicale